GB Group Ord Shs GBGPF

CanniMed Therapeutics Forms Special Committee for Potential

[Gladiator3]

CanniMed Therapeutics Forms Special Committee for Potential Unsolicited Offer from Aurora Cannabis

CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX:CMED) announced that it has formed a special committee of independent directors (“the Special Committee”) in anticipation of a potential formal offer from Aurora Cannabis Inc. (“Aurora”) for all of the issued and outstanding CanniMed shares.

Upon receipt, the Special Committee and the board of directors of CanniMed (the “Board”) will review the Proposal, in consultation with their respective legal and financial advisors, and will respond in due course.

CanniMed shareholders are reminded that they have an attractive and accretive transaction available to them now. CanniMed’s acquisition of Newstrike Resources Ltd. (TSX-V: HIP) will create a premier global cannabis company that is uniquely positioned to offer innovative, high quality products with two top tier distinct brands uniquely positioned to address key product trends and emerging drivers of growth in the medical and adult-use recreational cannabis markets. The addition of Up Cannabis Inc. and a strategic partnership with The Tragically Hip to the Company allow us to realize our strategy to become the preeminent cannabis leader in Canada and worldwide. The combined company will have increased operational scale with a targeted 45,000 kg of production capacity by 2019, improved capital markets presence with a pro-forma capitalization exceeding $500mm, and is expected to be accretive (before synergies) on key metrics by 2019.

Shareholders are advised to take no action on any proposal from Aurora until they have received further communication through the Director’s Circular, which will be provided to shareholders as soon as practical.

Shareholders with questions should call CanniMed’s strategic shareholder services advisor, Kingsdale Advisors, at 1-888-518-1554.

Advisors

Kingsdale Advisors is acting as strategic shareholder and communications advisor. AltaCorp Capital Inc. is acting as financial advisor to the Board and Borden Ladner Gervais LLP is acting as legal advisor to the Board. Cormark Securities Inc. is acting as financial advisor to the Special Committee and Stikeman Elliott LLP is acting as legal advisor to the Special Committee.

Read more at https://www.stockhouse.com/news/press-releases/2017/11/22/cannimed-therapeutics-forms-special-committee-for-potential-unsolicited-offer#x2YIC2dLxzP25tPD.99

[VENMan]

Even ACB shareholders want to know what the dilution will be when this deal is done. You have to lock-in what amount of shares ACB is willing to give CMED shareholders period and then if the price of the stock goes up or down for ACB and CMED you live with it. ACB can't keep saying CMED shareholders might get 4.53 per share or maybe less because Big Wigs that hold ACB shares cannot determine

[VENMan]

The 20 VWAP based on closing prices for ACB not including todays trading day is $5.06 as I calculate it. If ACB wants to give CMED $24 then hand over 4.75 ACB shares for every CMED and keep it that way no matter what happens to ACB shares on a trading day up or down. It's always 4.75 ACB shares for 1 CMED share. Doing somthing like this the market will know exactly how much dilution will

[Rockpaperstock]

THAT my friend is a great idea.  Let's hope someone from this special committee reads this and gets the hint!

[Valuewalk]

The special committee should be renamed the committee of special people, as they are not smart and will be against anything other than job preservation. The main thing here is that they formed a special committee, which means they expect the formal bid to come. That is good for us and the share price. They may sweeten or make the share calculation more specific but the main point here is getting

[GreyMatter22]

It is true that ACB is trading at all time highs, but CMED is also trading at all time high as well, in fact the price from $15 jumped to the $19-21 range as soon as ACB interest came about. I would prefer ACB over HIP of all companies anyway.

[VENMan]

CMED share price should have jumped from $15 because ACB offered a premium of 59% IF they give CMED shareholders 4.75 a share for every CMED share. In this current offer IFf the price of ACB gos to $12 CMED shareholders might only get 2 shares of ACB. The only reason ACB is having a run up in it's share price is because it's taking over CMED and it's in the news everyday. Some Analysts